However, clinical trials testing the use of EGFR inhibitors in endocrine treatment resistant ER+ breast cancer have produced modest or negative results[13] suggesting that further insight into underlying mechanisms for RTKs and ER interactions are required for successful translation of this aspect of ER function. This evidence concerns the gene ESR1 and breast cancer.